Bratschi Ltd
Felix Kesselring leads the Zurich based team at Bratschi Ltd, known for its ‘fortress of knowledge’ and ‘acute intellectual prowess’. The group excels at advising on the full gamut of matters, including reimbursements, administrative procedures, and innovation management. The team is also noted for its deep regulatory and contentious expertise, frequently assisting clients with drug pricing cases and laboratory services. Kesselring regularly acts for both Swiss and international clients within the medical device, pharma, and healthcare industries, while Yaël Heymann‘s primary area of focus is on regulatory issues involving data protection and healthcare law.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Great communication. Quick responses and understanding of the issues. Very meticulous work.’
‘In-depth knowledge of laws and regulation in the pharmaceutical industry.’
‘We work with Felix Kesselring for his unique expertise in laws and regulations related to life sciences’
‘Bratschi Ltd astounds with its exemplary team, wielding a unique blend of legal acumen and scientific insight, ensuring that it not only understands the law but also profoundly grasps the science behind client innovations. They navigate regulatory complexities with finesse and strategic savvy unparalleled in the marketplace. The team exemplifies a q and strategic thinking in regulatory compliance.’
‘The individuals at Bratschi Ltd’s practice epitomise a blend of acute intellectual prowess and genuine dedication to client success, setting a high bar in the legal and scientific consulting arena. What markedly distinguishes them from peers in the competitive landscape is their unwavering commitment to ethical practice, client transparency, and a palpable passion for driving healthcare innovations forward.’
‘Felix Kesselring is clearly the go-to person for healthcare and life science matters in Switzerland - for Swiss or international clients. This pan-European knowledge makes Felix very valuable, particularly for Swiss pharma companies which export pharmaceuticals abroad.’
‘Dr. Felix Kesseling: quick feedback, realistic assessment of the opportunities and risks, industry experience’
‘The team is specialised in Swiss regulatory matters and has ample experience with Swissmedic. They are very thorough and detail oriented in their work and the work results delivered are precise. They did not shy away from reviewing an impressive amount of rather technical documents and were able to perform a helpful risk assessment.’
Key clients
- Zur Rose Suisse Ltd.
- Daiichi Sankyo (Schweiz) Ltd.
- Otto Group
- Ortsbürgergemeinde St. Gallen
- Neuraxpharm Switzerland Ltd.
- Post CH Ltd.
- Gilead Sciences Switzerland LLC
- Smith & Nephew Orthopaedics Ltd.
- Sigma Aldrich Production GmbH
- CSL Behring Ltd.
- IGEN Biolab Group Ltd.
- Kantonsspital St. Gallen
- Spitalregion Fürstenland-Toggenburg
- Oertli-Instrumente AG
Work highlights
- Advised Otto Group on the acquisition of the Medgate, a provider of digital health services, and Better Doc, provider of services in the field of medical quality data analysis.
- Represented Neuraxpharm Switzerland Ltd. before the Federal Supreme Court against price reductions for one of its medicinal products.
- Advised Daiichi Sankyo (Schweiz) Ltd. on the development of a digital health app.
Lawyers
Next Generation Partners
Practice head
The lawyer(s) leading their teams.
Felix Kesselring